Virexit Technologies, Inc. Secures Direct U.S. Rights to Distribute Airros(TM) Sanitation System

ECONOMY 15.05.2025

High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows - POISED TO DRIVE 35% OPERATIONAL PROFIT

Text size:

NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 / VirExit Technologies, Inc. (OTC PINK:VXIT) ("VirExit" or the "Company"), a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE"). This agreement establishes VirExit as the U.S. distributor of AirROS's patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027.

Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 - 30.5% of total AirROS sales, scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.

3 Year Revenue Forecast

FY Period	Total Revenue	Service & Maint Gross Margin (%) / year	Hardware Units Gross Margin (%)	Blended Gross Margin (%)	SG&A (% of Rev)	Operational Profit (%)
2H FY25 (5 Pilot Programs)	$196,721	51.8%	55%	53.0%	18.0%	35%
FY26 (20 Unit Installs)	$786,885	51.8%	55%	53.0%	18.0%	35%
FY27 (40 Unit Installs)	$1,573,770	51.8%	55%	53.0%	18.0%	35%

_*_{Deployment Ramp -}_{2H-FY 25': 5 pilot sites; FY 26': 20 deployments; FY 27': 40 deployments; All located in major metropolitan markets to maximize visibility and service efficiency; Sales, installation and support teams staged in target metros. Lab-testing and HVAC partners engaged locally to maintain margins.}

Disruptive Technology Meets Rapid Market Expansion
AirROS's proprietary ROS technology continuously neutralizes viruses, bacteria, molds and odors-without chemical residues-earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening IAQ mandates in schools, healthcare and hospitality, VirExit's nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.

"By combining SAGE's breakthrough ROS platform with VirExit's proven go-to-market engine, we're not only enhancing safety but unlocking a durable, subscription-driven growth engine," said James Katzaroff, CEO of VirExit Technologies. "Investors should expect steady quarterly revenue inflections, robust margin expansion and a clear pathway to positive cash flow by mid-2026."

"VirExit's market reach and ESG-aligned vision make them the ideal partner to scale AirROS," added Brian Taylor, CEO of SAGE Industrial. "Together, we'll set a new industry benchmark in continuous, on-site sanitation."

Consumer Market Expansion & Public Health Impact
To complement our B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).

Mold & Indoor Allergens
- Current State: Roughly 50 % of U.S. homes contend with visible mold or dampness; up to 20 % of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).
- AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99 %, reducing allergy flare-ups and related healthcare costs.
Childhood Asthma & Seasonal Pathogens
- Current State: Asthma affects 1 in 13 Americans (≈ 25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.
- AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40 %, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.
Elderly & Immunocompromised Households
- Current State: As immune defenses wane with age, older adults (12 % of the U.S. population) face higher rates of respiratory infections and hospital admissions-burdening families and the healthcare system.
- AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.

By bridging our enterprise and consumer offerings, VirExit not only multiplies its addressable market-but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.

Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals-Office Buildings (US $1.2 B market, delivering 10-20% HVAC savings and 35% fewer sick-days), Schools & Universities (US $0.7 B market, driving a 30% drop in absenteeism), and Long-Term Care (US $1.0 B market, achieving 40% fewer hospital-acquired infections).

After validating these results, VirExit will extend into 15 major metro areas-rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2-7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS's upfront investment-recouped through energy savings, reduced maintenance, and fewer sick-day losses-pays for itself in under 18 months, delivering a full return within a year and a half. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.

Vertical	Current Pain Point / Infrastructure Gap	US Market (2024)	Global Market (2024)	Cost-Saving & Revenue Benefits	Occupant Benefits
Office Buildings	"Sick building syndrome"• High HVAC energy spend	$1.2 B	$3.4 B	10-20% lower HVAC costs• 35% fewer sick-days (~$300/emp./yr)	+15% cognitive performance• Reduced absenteeism• Higher employee morale
Hotels & Restaurants	Odor/stale-air complaints• Heavy chemical cleaning	$0.9 B	$2.6 B	+5% occupancy lift• +10% F&B revenue• Lower chemical spend	Enhanced guest comfort• Fewer negative reviews• Higher return visits
Schools & Universities	Aging HVAC• High absenteeism	$0.7 B	$1.8 B	30% drop in absenteeism (>$400/student/yr)• Reduced HVAC maintenance	Improved attention & test scores• Safer learning environment
Long-Term Care	Poor infection control• Regulatory compliance risk	$1.0 B	$2.8 B	40% fewer HAIs• Avoidance of fines/penalties	Better resident health & comfort• Lower staff turnover
Retail	Uneven air quality• Low shopper dwell time	$0.8 B	$2.1 B	+15% dwell time → +5% sales lift• Reduced shrinkage	More enjoyable shopping• Increased customer loyalty
Commercial & Government	Outdated HVAC• Costly retrofits• Compliance mandates	$1.0 B	$3.0 B	Avoid $1 M+ in retrofit costs• Demonstrated regulatory compliance	Higher employee productivity• Enhanced public trust
Apartment Complexes	Poorly ventilated common areas• High tenant turnover	$0.6 B	$1.6 B	10% reduction in churn• Fewer maintenance tickets	Healthier living spaces• Higher tenant satisfaction
Cannabis Cultivation	Mold & humidity control• Crop-loss risk	$0.2 B	$0.5 B	+15% yield increase• -20% pathogen-related loss	Safer work environment• Regulatory peace of mind
Grocery Stores	Rapid spoilage• Contamination risk	$0.5 B	$1.3 B	+7-14 day shelf-life → -3% waste• Higher produce margins	Greater consumer confidence• Better food safety
Fitness Facilities	Poor airflow in gyms/studios• Member health complaints	$0.4 B	$1.0 B	-15% membership churn• Lower cleaning & HVAC costs	Healthier workouts• Reduced risk of airborne illness
Daycare Centers	Frequent outbreaks → closures	$0.2 B	$0.5 B	-50% outbreak events• Avoided closure & liability costs	Safer child-care environment• Peace of mind for parents
Pro Sports Arenas	High transmission risk in crowds	$0.15 B	$0.4 B	+10% ticket renewals• Lower staff sick-leave payouts	Safer fan experience• Reduced player/staff illness

Forward-Looking Statements
This release contains forward-looking statements regarding our expectations for future performance. Actual results may differ materially. See the Company's filings with OTC Markets for a full discussion of risk factors and safe-harbor provisions.

About VirExit Technologies, Inc.
VirExit Technologies, Inc. is a U.S. reseller and marketer of AirROS™-a patented reactive oxygen species (ROS) air-and-surface sanitation platform proven in independent labs to reduce pathogens by 99.99% within 30 minutes. AirROS™ solutions are offered through recurring-revenue service agreements for healthcare, senior living, commercial real estate, hospitality, education, and residential customers. For more information, visit virexittechnologies.com.

Address:
1280 Lexington Avenue
FRNT2 #1292
New York, NY 10028

Please feel free to contact us or follow us on Twitter / X, to learn more.

Contact:
VirExit Technologies, Inc.
James C Katzaroff, CEO
Phone: +1 509-531-1671
[email protected]

Investor Relations:
Email: [email protected]

Website:
Visit: www.virexittechnologies.com

SOURCE: VirExit Technologies, Inc.

View the original press release on ACCESS Newswire

M.Cunningham--TFWP